Companies: 10,795·Total market cap: $144.5T

Vivos Therapeutics, Inc.

Vivos Therapeutics, Inc.

VVOSNASDAQHealthcare● Active

$0.87

+$0.01(+0.64%)

Market Cap$5123882

P/E Ratio—

52W High$7.95

52W Low$0.545

Avg Volume227K

Open$0.82

Beta6.08

Net Income Financials Revenue

Vivos Therapeutics, Inc. (VVOS) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

VVOS · net income · updated Jun 9, 2026

Core profitability metrics

VVOS · net income · margin · TTM · CAGR

Net income was −$21.2M for FY2025 (fiscal year ending 2025-12-31), down 90.6% year-over-year. Net profit margin was -121.7%.

FY2025 Net Income−$21.2M▼ -90.6% YoY

Trailing 12M (TTM)−$25.1Mtrailing 4 quarters sum

Net Profit Margin-121.7%−$21.2M ÷ $17.4M

YoY Change-90.6%—

5-Year CAGRN/AN/A — contains loss years

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 9, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %

▸ FMP /income-statement · Annual · VVOS net income history · VVOS profit margin

Annual net income data

VVOS · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2025Loss−$21.2M▼ 90.6%-121.7%$17.4M

FY2024Loss−$11.1M▲ +18.0%-74.1%$15.0M

FY2023Loss−$13.6M▲ +43.0%-98.4%$13.8M

FY2022Loss−$23.8M▼ 17.5%-148.8%$16.0M

FY2021Loss−$20.3M▼ 68.3%-120.2%$16.9M

Net income vs peers (Healthcare)

VVOS vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

#1

Vivos Therapeutics, Inc.YOU

VVOS

−$21.2M-90.6%-121.7%

Loss

Johnson & Johnson

$26.80B+90.6%28.5%

Eli Lilly and Company

$20.64B+94.9%31.7%

UnitedHealth Group Incorporated

$12.06B-16.3%2.7%

$4.23B-1.2%6.9%

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

Vivos Therapeutics, Inc. (VVOS) reported net income of −$21.2M for FY2025 (fiscal year ending 2025-12-31), down 90.6% year-over-year. The net profit margin was -121.7% — meaning the company kept $-1.22 of every dollar of revenue as profit.

Vivos Therapeutics, Inc. has not yet achieved annual profitability based on available data (8 fiscal years). The company has reported net losses across all available periods.

Vivos Therapeutics, Inc.'s net profit margin was -121.7% for FY2025, based on the latest annual results.

Investors sometimes search for "Vivos Therapeutics, Inc. net worth" — the company's market capitalization is a separate figure from VVOS net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

VVOS net income · 4 questions

Vivos Therapeutics, Inc. is not currently profitable on an annual basis. The company reported a net loss of $21.2M for FY2025.

is VVOS profitabledoes VVOS make a profitVVOS profitabilityVVOS profitable company

▸ Source: FMP /income-statement · GAAP · Vivos Therapeutics, Inc. · Vivos Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026